E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | HLGT |
E.1.2 | Classification code | 10039911 |
E.1.2 | Term | Seizures (incl subtypes) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the efficacy of Keppra XR compared with a historical control, in the conversion to monotherapy treatment of partial onset seizures. |
|
E.2.2 | Secondary objectives of the trial |
Secondary objective: To assess the safety and tolerablity of two doses of Keppra XR, in the conversion to monotherapy treatment of partial onset seizures.
Exploratory objective: To explore the direct medical resource use and indirect cost parameters. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Male or female subjects 12 to 75 years of age Signed and dated written informed consent. Signed and dated written assent, if applicable. Subjects must have inadequately controlled partial onset epilepsy with observable partial seizures that may be classified as simple complex or partial seizures evolving to secondary generalized seizures according to ILAE classification Subjects must be experiencing 2 to 40 seizures per 4-week period while being maintained on at least one, but no more than two standard AEDs, and auras are not being included in the seizure count. Subjects must be on a stable dose for at least four weeks before Screening (Visit 1) of at least one, but no more than two other concomintant antiepileptic drugs (AEDs) If taking two AEDs, one of the baseline AEDs should be taken at less than or equal to 50% of the minimum recommended dose EEG must be consistent with localization related epilepsy Previous CT scan or MRI confirming the subject is free of neoplasia, progressive cerebral disease or any other progressively neurodegenerative disease Female subjects without childbearing potential are eligible. Female subjects with childbearing potential are eligible if they use a medically accepted contraceptive method. The subjects must understand the consequences and potential risks of inadequately protected sexual activity, be educated about and understand the proper use of contraceptive method, and undertake to inform the Investigator of any potential change in status. Subjects must be capable of understanding and completing diaries and adhering to the protocol |
|
E.4 | Principal exclusion criteria |
Females who are lactating or pregnant A history of status epilepticus in the 6 months preceeding randomization Seizures that are uncountable due to clustering during the 8-week period prior to Screening (Visit 1) and during the 8-week Baseline Period Significant medical, psychiatric or neurological illness Benzodiazepine use Suspected substance or alcohol abuse within 12 months preceding randomization Use of any medication (other than concomitant AEDs) that influences the central nervous system (CNS) unless on a stable regimen for at least 4 weeks prior to Screening History of previous treatment with levetiracetam or sensitivity to levetiracetam Use of an investigational drug or device in the 4 months preceding randomization Subjects may not enter the study if they are presently receiving phenobarbital, mysoline, or felbamate, or have an activated VNS device Neuroleptics and traditional herbal AEDs are not allowed History of recurrent psychotic or major affective disorder or suicide attempts History or presence of pseudoseizures Subjects on ketogenic diet Subjects with digestive problems that could impair the absorption of the Keppra XR formulation History of poor compliance with visit schedule or medication intake Subjects taking part in another clinical/pharmacological study in the 30 days prior to Screening (Visit 1) Subjects with any medical or surgical condition that might interfere with the subject's study participation, i.e. scheduled elective surgery, etc. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy endpoint is the cumulative exit rate at 112 days after the beginning of the previous AED tapering phase. Subjects will be required to exit the study if they experience any of the following protocol-defined exit events: 1) a twofold increase in partial seizure frequency in any 4-week treatment period compared to baseline; 2) a twofold increase in the highest 2-day consecutive seizure frequency that occured during the baseline phase; 3) occurance of a generalized seizure if none had occured in the 6 months prior to randomization; or 4) an episode of status epilepticus of a prolongation or worsening of seizure duration or frequency considered by the investigator to require intervention. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 10 |
E.8.5 | The trial involves multiple Member States | No |
E.8.5.1 | Number of sites anticipated in the EEA | 10 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
*Subjects who qualify can enter the long term follow-up study N01281. The end of the subject's participation in the study will be confirmed on the CRF. All data about the subject's status (study completion or reason for early termination) at the end of the study will be recorded. It will be specified: -Whether the subject completed or discontinued the study. -Whether their is still and unresolved AE at the end of the study. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 5 |
E.8.9.2 | In all countries concerned by the trial days | 0 |